Amneal Pharmaceuticals (AMRX) Barclays 28th Annual Global Healthcare Conference summary

Strategic overview and recent performance

• Achieved strong fiscal 2025 results, exceeding guidance and setting a positive outlook for 2026 and beyond.

• Diversified business through acquisitions, notably AvKARE, and expanded into specialties and biosimilars.

• Affordable Medicines Group, encompassing generics, injectables, and biosimilars, grew 5% over five years and is expected to accelerate to high single-digit growth.

• Specialty segment saw robust launches, especially CREXONT, which outperformed expectations and is positioned for significant growth.

• Recognized as Best Company to Work For by BioSpace, marking a milestone for an affordable medicines company.

Segment performance and growth drivers

• Retail generics channel is expanding, with a strong pipeline including ophthalmics, transdermals, and inhalation products.

• Injectables focus on complex launches, such as long-acting depot and iohexol, with a robust growth pipeline.

• Biosimilars segment poised for rapid growth with upcoming launches (denosumab in 2026, XOLAIR in 2027) and potential M&A to expand the portfolio.

• Margin improvements expected due to manufacturing integration and recent FDA regulatory changes reducing development costs.

• Specialty products CREXONT and Brekiya are exceeding initial uptake projections, with CREXONT targeting $300M–$500M peak sales.

Business model adjustments and profitability

• De-emphasized low-margin distribution within AvKARE, focusing on profitable government channels (VA/DoD) and direct distribution.

• Revenue impact from exiting low-margin segments offset by improved EBITDA and profitability in core businesses.

• Specialty segment steady in 2026 despite RYTARY LOE, with CREXONT and Brekiya filling the gap.

• AvKARE’s government business remains a core, stable contributor, leveraging U.S.-based manufacturing for compliance and margin benefits.